Ac-SDKP Evidence Guide
Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol.
Our Take
Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol.
- Evidence context
- Anti-fibrotic mechanistic research, kidney and cardiac fibrosis models (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol
Benefits and Evidence
- Cardiac Anti-Fibrosis: Level D, mostly non-human evidence - Animal studies consistently demonstrate reduction in cardiac fibrosis and improved ventricular function in models of hypertension, myocardial infarction, and diabetic cardiomyopathy.
- Renal Fibrosis Prevention: Level D, mostly non-human evidence - Preclinical evidence shows reduced renal interstitial fibrosis and preserved kidney function in models of chronic kidney disease and diabetic nephropathy.
- Hematopoietic Stem Cell Protection: Level C, includes human evidence - Early human studies and extensive preclinical work demonstrate protection of hematopoietic stem cells from chemotherapy-induced damage by maintaining quiescence.
Side Effects and Warnings
- No significant adverse effects reported in preclinical studies
- Theoretical hypotensive effect at high doses
- Very limited human safety data
- Not approved for clinical use
- Extremely short half-life limits practical application
- Endogenous levels are regulated by ACE; exogenous supplementation effects are not fully characterized
- All evidence is predominantly preclinical
Research Dosage References
- <strong>Subcutaneous injection</strong> - 100-800 mcg/kg/day - Continuous infusion or divided doses - Primarily studied via osmotic minipump in animal models. Rapid degradation by ACE necessitates continuous delivery or ACE inhibitor co-administration.
Mechanism of Action
Ac-SDKP exerts anti-fibrotic and protective effects through: 1. TGF-beta/Smad pathway inhibition: Blocks TGF-beta1-induced fibroblast activation and collagen synthesis by inhibiting Smad2/3 phosphorylation. 2. Hematopoietic stem cell regulation: Prevents premature entry of hematopoietic stem cells into S-phase, protecting them from cytotoxic damage. 3. Macrophage polarization: Promotes M2 anti-inflammatory macrophage phenotype, reducing inflammatory tissue damage. 4. Endothelial protection: Enhances endothelial cell function and promotes angiogenesis in ischemic tissues.
Legal Status
Ac-SDKP is a research compound not approved for clinical use in any country. It is not a controlled substance. Available for research purposes only.
Primary Sources
- N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction in rats. Hypertension, 2003.
- Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts. Circ Res, 2003.
- The role of Ac-SDKP in the anti-fibrotic mechanism of ACE inhibitors. Curr Opin Pharmacol, 2009.
Quick Answers
Where is the strongest evidence for Ac-SDKP?
Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol. Evidence context: Anti-fibrotic mechanistic research, kidney and cardiac fibrosis models (preclinical only).
What are the main side effects of Ac-SDKP?
Ac-SDKP side effects and warning signals include No significant adverse effects reported in preclinical studies, Theoretical hypotensive effect at high doses, Very limited human safety data, Not approved for clinical use, and Extremely short half-life limits practical application.
What evidence level is Ac-SDKP?
Ac-SDKP is rated Level D; the listed research status is Preclinical.